OGA Inhibitor
Showing 1 - 25 of 7,358
Alzheimer Trial in Worldwide (LY3372689, Placebo)
Active, not recruiting
- Alzheimer Disease
- LY3372689
- Placebo
-
Canoga Park, California
- +70 more
Jan 18, 2023
Metastatic Esophageal Cancer, Metastatic Gastric Cancer Trial in Sutton (Atezolizumab)
Recruiting
- Metastatic Esophageal Cancer
- Metastatic Gastric Cancer
-
Sutton, Surrey, United KingdomThe Royal Marsden NHS Foundation Trust
Jul 12, 2021
Peripheral T Cell Lymphoma Trial in Beijing (Linperlisib in combined with Chidamide)
Recruiting
- Peripheral T Cell Lymphoma
- Linperlisib in combined with Chidamide
-
Beijing, Beijing/China, China
- +1 more
Oct 9, 2023
Cutaneous T-cell Lymphoma Trial in Beijing (Linperlisib in combined with Chidamide)
Recruiting
- Cutaneous T-cell Lymphoma
- Linperlisib in combined with Chidamide
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Sep 8, 2023
Cervical Cancer Trial in Amsterdam (Anti-PD-1 antibody balstilimab)
Not yet recruiting
- Cervical Cancer
- Anti-PD-1 antibody balstilimab
-
Amsterdam, NetherlandsAmsterdam UMC
Oct 17, 2023
Hepatocellular Carcinoma (HCC) Trial in Taiwan (Chidamide, Regorafenib)
Recruiting
- Hepatocellular Carcinoma (HCC)
-
Kaohsiung, Taiwan
- +4 more
Mar 14, 2023
Chronic Kidney Disease Trial (Part A - Lorundrostat QD + Dapaglifozin QD, Part A - Lorundrostat QD, Part B - Lorundrostat QD
Not yet recruiting
- Chronic Kidney Disease
- Part A - Lorundrostat QD + Dapaglifozin QD
- +2 more
- (no location specified)
Nov 27, 2023
Differentiated Thyroid Cancer Trial in Pavia (Pembrolizumab)
Not yet recruiting
- Differentiated Thyroid Cancer
-
Pavia, Lombardia, ItalyIstituti Clinici Scientifici Maugeri
May 5, 2023
Blood Vessel Function in Postmenopausal Women With Breast Cancer
Active, not recruiting
- Breast Cancer
- anastrozole
- +3 more
-
Rochester, MinnesotaMayo Clinic
Jan 17, 2023
Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma Trial in Boston (CB-103,
Not yet recruiting
- Adenoid Cystic Carcinoma
- +2 more
- CB-103
- +2 more
-
Boston, MassachusettsDana Farber Cancer Institute
Mar 14, 2023
Healthy Trial in Biberach (BI 1810631, Itraconazole)
Recruiting
- Healthy
- BI 1810631
- Itraconazole
-
Biberach, GermanyHumanpharmakologisches Zentrum Biberach
Apr 27, 2023
Vonoprazan, Helicobacter Pylori Infection, Proton Pump Inhibitor Trial in Hangzhou (Tegoprazan, Esomeprazole)
Active, not recruiting
- Vonoprazan
- +2 more
-
Hangzhou, Zhejiang, ChinaHangzhou first people's Hospital
Dec 2, 2022
Atypical Hemolytic Uremic Syndrome (aHUS) Trial in Worldwide (Ravulizumab)
Active, not recruiting
- Atypical Hemolytic Uremic Syndrome (aHUS)
- Ravulizumab
-
Aurora, Colorado
- +19 more
Nov 16, 2022
Vonoprazan, Helicobacter Pylori Infection, Proton Pump Inhibitor Trial in Hangzhou (Vonoprazan Tablets, Amoxicillin Capsules,
Recruiting
- Vonoprazan
- +2 more
- Vonoprazan Tablets
- +2 more
-
Hangzhou, Zhejiang, ChinaHangzhou first people's Hospital
Nov 23, 2022
Her-2 Negative Breast Cancer, HRR Gene Mutation Trial in Guangzhou (Camrelizumab, Fluzoparib, Nab-paclitaxel)
Recruiting
- Her-2 Negative Breast Cancer
- HRR Gene Mutation
- Camrelizumab
- +2 more
-
Guangzhou, Guangdong, ChinaFirst Affiliated Hospital, Sun Yat-Sen University
Mar 7, 2023
Breast Cancer Trial in Wuhan (Adebrelimab, dalpiciclib)
Recruiting
- Breast Cancer
-
Wuhan, Hubei, ChinaTongji Hospital Affiliated of Tongji Medical College Huazhong Un
Nov 20, 2023
Examining the Effect of Endocrine Therapy on Aging
Recruiting
- Breast Neoplasm Female
- +2 more
- Aromatase inhibitor
-
Ann Arbor, MichiganUniversity of Michigan Rogel Cancer Center
Jan 17, 2023
Healthy Male Trial in Shanghai (D-1553)
Active, not recruiting
- Healthy Male
-
Shanghai, Shanghai, ChinaShanghai Xuhui District Central Hospital
Oct 23, 2023
Metastatic Breast Cancer Trial in Seoul (Fulvestrant plus AI plus ribociclib, AI plus ribociclib)
Not yet recruiting
- Metastatic Breast Cancer
- Fulvestrant plus AI plus ribociclib
- AI plus ribociclib
-
Seoul, Korea, Republic ofKorea university Guro hospital
Apr 16, 2023
Diabetes, Cellular Senescence, Sodium-Glucose Transporter 2 Inhibitors Trial in Seoul (SGLT2 inhibitor, Glimepiride)
Not yet recruiting
- Diabetes Mellitus
- +2 more
- SGLT2 inhibitor
- Glimepiride
-
Seoul, Korea, Republic ofYonsei University College of Medicine
Aug 1, 2023